Clinical pharmacology of etintidine in patients with duodenal ulcer

D. C. Brater, W. M. Meyers, K. A. Dandekar, K. A. Pittman, W. Peterson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The gastric antisecretory activity of etintidine, a new histamine H2-receptor antagonist, was evaluated in 5 patients with quiescent duodenal ulcer disease. Meal-stimulated acid secretion was measured after 100 and 300 mg oral doses of etintidine, 100 and 300 mg oral doses of cimetidine, and placebo. Reductions from placebo in four-hour gastric acid secretion were 49, 65, 80, and 94%, with 100 mg cimetidine, 100 mg etintidine, 300 mg cimetidine, and 300 mg etintidine, respectively. Drug concentrations in plasma were determined by HPLC. The pharmacokinetics of the 2 drugs were similar. We analyzed sigmoid-shaped concentration-response curves to both agents; the concentrations causing 50% inhibition of meal-stimulated gastric acid secretion were 0.44±0.04 and 0.15±0.04 μg/ml for cimetidine and etintidine, respectively. However, characteristics of these curves were such that the potency difference diminished at higher concentrations.

Original languageEnglish (US)
Pages (from-to)495-500
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume23
Issue number6
DOIs
StatePublished - Nov 1982

Fingerprint

Clinical Pharmacology
Duodenal Ulcer
Cimetidine
Gastric Acid
Meals
Placebos
Duodenal Diseases
Histamine H2 Antagonists
Sigmoid Colon
Pharmaceutical Preparations
Stomach
Pharmacokinetics
High Pressure Liquid Chromatography
etintidine
Acids

Keywords

  • cimetidine
  • duodenal ulcer
  • etintidine
  • gastric acidity
  • histamine H antagonist
  • pharmacodynamics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Brater, D. C., Meyers, W. M., Dandekar, K. A., Pittman, K. A., & Peterson, W. (1982). Clinical pharmacology of etintidine in patients with duodenal ulcer. European Journal of Clinical Pharmacology, 23(6), 495-500. https://doi.org/10.1007/BF00637495

Clinical pharmacology of etintidine in patients with duodenal ulcer. / Brater, D. C.; Meyers, W. M.; Dandekar, K. A.; Pittman, K. A.; Peterson, W.

In: European Journal of Clinical Pharmacology, Vol. 23, No. 6, 11.1982, p. 495-500.

Research output: Contribution to journalArticle

Brater, DC, Meyers, WM, Dandekar, KA, Pittman, KA & Peterson, W 1982, 'Clinical pharmacology of etintidine in patients with duodenal ulcer', European Journal of Clinical Pharmacology, vol. 23, no. 6, pp. 495-500. https://doi.org/10.1007/BF00637495
Brater, D. C. ; Meyers, W. M. ; Dandekar, K. A. ; Pittman, K. A. ; Peterson, W. / Clinical pharmacology of etintidine in patients with duodenal ulcer. In: European Journal of Clinical Pharmacology. 1982 ; Vol. 23, No. 6. pp. 495-500.
@article{2f5d011ede744d4ebd4d5c019b4a29c2,
title = "Clinical pharmacology of etintidine in patients with duodenal ulcer",
abstract = "The gastric antisecretory activity of etintidine, a new histamine H2-receptor antagonist, was evaluated in 5 patients with quiescent duodenal ulcer disease. Meal-stimulated acid secretion was measured after 100 and 300 mg oral doses of etintidine, 100 and 300 mg oral doses of cimetidine, and placebo. Reductions from placebo in four-hour gastric acid secretion were 49, 65, 80, and 94{\%}, with 100 mg cimetidine, 100 mg etintidine, 300 mg cimetidine, and 300 mg etintidine, respectively. Drug concentrations in plasma were determined by HPLC. The pharmacokinetics of the 2 drugs were similar. We analyzed sigmoid-shaped concentration-response curves to both agents; the concentrations causing 50{\%} inhibition of meal-stimulated gastric acid secretion were 0.44±0.04 and 0.15±0.04 μg/ml for cimetidine and etintidine, respectively. However, characteristics of these curves were such that the potency difference diminished at higher concentrations.",
keywords = "cimetidine, duodenal ulcer, etintidine, gastric acidity, histamine H antagonist, pharmacodynamics",
author = "Brater, {D. C.} and Meyers, {W. M.} and Dandekar, {K. A.} and Pittman, {K. A.} and W. Peterson",
year = "1982",
month = "11",
doi = "10.1007/BF00637495",
language = "English (US)",
volume = "23",
pages = "495--500",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacology of etintidine in patients with duodenal ulcer

AU - Brater, D. C.

AU - Meyers, W. M.

AU - Dandekar, K. A.

AU - Pittman, K. A.

AU - Peterson, W.

PY - 1982/11

Y1 - 1982/11

N2 - The gastric antisecretory activity of etintidine, a new histamine H2-receptor antagonist, was evaluated in 5 patients with quiescent duodenal ulcer disease. Meal-stimulated acid secretion was measured after 100 and 300 mg oral doses of etintidine, 100 and 300 mg oral doses of cimetidine, and placebo. Reductions from placebo in four-hour gastric acid secretion were 49, 65, 80, and 94%, with 100 mg cimetidine, 100 mg etintidine, 300 mg cimetidine, and 300 mg etintidine, respectively. Drug concentrations in plasma were determined by HPLC. The pharmacokinetics of the 2 drugs were similar. We analyzed sigmoid-shaped concentration-response curves to both agents; the concentrations causing 50% inhibition of meal-stimulated gastric acid secretion were 0.44±0.04 and 0.15±0.04 μg/ml for cimetidine and etintidine, respectively. However, characteristics of these curves were such that the potency difference diminished at higher concentrations.

AB - The gastric antisecretory activity of etintidine, a new histamine H2-receptor antagonist, was evaluated in 5 patients with quiescent duodenal ulcer disease. Meal-stimulated acid secretion was measured after 100 and 300 mg oral doses of etintidine, 100 and 300 mg oral doses of cimetidine, and placebo. Reductions from placebo in four-hour gastric acid secretion were 49, 65, 80, and 94%, with 100 mg cimetidine, 100 mg etintidine, 300 mg cimetidine, and 300 mg etintidine, respectively. Drug concentrations in plasma were determined by HPLC. The pharmacokinetics of the 2 drugs were similar. We analyzed sigmoid-shaped concentration-response curves to both agents; the concentrations causing 50% inhibition of meal-stimulated gastric acid secretion were 0.44±0.04 and 0.15±0.04 μg/ml for cimetidine and etintidine, respectively. However, characteristics of these curves were such that the potency difference diminished at higher concentrations.

KW - cimetidine

KW - duodenal ulcer

KW - etintidine

KW - gastric acidity

KW - histamine H antagonist

KW - pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=0020462519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020462519&partnerID=8YFLogxK

U2 - 10.1007/BF00637495

DO - 10.1007/BF00637495

M3 - Article

VL - 23

SP - 495

EP - 500

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -